Newsletter

You can unsubscribe from this list at any time by sending an e-mail message to
stellarstocks-request@listserv.stellarstocks.com. Put "UNSUBSCRIBE" in the subject line and you will be automatically removed. You can also unsubscribe by going to http://listserv.stellarstocks.com and entering your
email address there while selecting unsubscribe.


Stellarstocks Newsletter
April 26, 1999	Volume II, Issue 17

Email : info@stellarstocks.com
URL : http://www.stellarstocks.com

To Stellarstocks Subscribers:

Today there was exciting news on our most current profile, US Microbics (OTC BB: BUGS). If you have not read the original profile, we strongly encourage you to do so now, as the stock is trading up nicely on light, but consistent volume. The original profile can be found by Clicking Here.

The stock of US Microbics is up about 7% since releasing the profile back on April 9th. Today's news release gives us some specific information about the ramping up of production capacity that we originally covered. This news release informs us that the Company now has enough production capacity to fill the demand for at least 35 BioRaptors. This would equate to about $40 million in high margin annual sales to BioRaptors users that are operating at 80% capacity. The Company is very secretive about its profit margins, but we are confidant that $40 million in sales would equate to substantial profits for the Company.

We would also like to point out to our members that the stock of US Microbics has been an outstanding performer over the last year. It has outperformed the major indexes by a wide margin, and hopefully will continue to do so. The following is a chart showing the relative performance of US Microbics stock to the major indexes.

Index	Performance*
Dow Jones Industrial Average	+20.54%
S&P 500	+22.54%
NASDAQ	+40.21%
Russell 2000 Small Cap Index	-10.27%
US Microbics (OTC BB: BUGS)	+191.27%

*source: Bloomberg Charts 4/26: Click Here to view chart

Here is the press release for your review:

Monday April 26, 9:59 am Eastern Time
Company Press Release
SOURCE: U.S. Microbics, Inc

BUGS Increases Capacity in Anticipation of Sales Demand

CARLSBAD, Calif., April 26 /PRNewswire/ -- Robert Brehm, CEO of U.S. Microbics, Inc., (OTC Bulletin Board: BUGS - news), announced that West Coast Fermentation Center, a wholly owned subsidiary, has increased its manufacturing capacity with the installation of new equipment and additional staff in anticipation of pending sales of its patented Bio-Raptor(TM) process.

The Bio-Raptor is a portable, street legal, shredder, conveyor, sprayer system that utilizes proprietary microbial blends with a patented application process to quickly and inexpensively decontaminate soil, decompose green waste and remove odors, pathogen and weed seeds from animal effluent. In typical hydrocarbon cleanup applications, a Bio-Raptor would use approximately 40,000 pounds of microbial blends per year.

The West Coast Fermentation Center has recently expanded its capacity to meet this demand. In powder blending operations, a new 200 cu foot blender has been added which increases capacity to 30,000 #/week or approximately 1,500,000 #/year which should supply sufficient microbial blends for 35 Bio-Raptors per year. A new drying room has also been added to process liquid bugs received from out-sourced fermentation operations and a microbiology lab has recently been activated on site. New additions to the technical staff also include a microbiologist and biochemist, and additional personnel in maintenance, blending and shipping.

``The increased capacity should be sufficient for the next year unless sales demand exceeds our expectations'', said Brehm. ``We are receiving many inquiries about our agricultural blends which enhance plant growth and reduce water and fertilizer use. If we receive orders for these products, we may have to further increase our capacity. At this time we are only building to our anticipated needs for the next year.''

For further information about U.S. Microbics and their products contact Ric Eisenberg at 212-496-6828 or Robert Brehm at 760-918-1860 or visit the website at http://bugsatwork.com.

The information contained in this press release includes forward-looking statements. Forward-looking statements usually contain the words ``estimate,'' ``anticipate,'' ``believe,'' ``expect,'' or similar expressions, that involve risks and uncertainties. These risks and uncertainties include the Company's status as a startup company with uncertain profitability, need for significant capital, uncertainty concerning market acceptance of its products, competition, limited service and manufacturing facilities, dependence on technological developments and protection of its intellectual property. The Company's actual results could differ materially from those discussed herein. Factors that could cause or contribute to such differences are discussed more fully in the ``Risk Factors,'' ``Management's Discussion and Analysis or Plan of Operation'' and other sections of the Company's Form 10-KSB and other publicly available information regarding the Company on file with the Securities and Exchange Commission. The Company will provide you with copies of this information upon request.

SOURCE: U.S. Microbics, Inc.

Links to Downloads
1st Net and InterVu Audience Manager Software
InterVu EyeQ Multimedia Manager

Disclaimer

The Stellarstocks.com Newsletter is an independent electronic publication committed to providing our readers with factual information on selected publicly traded companies. All companies are chosen on the basis of certain financial analysis and other pertinent criteria with a view toward maximizing the upside potential for investors while minimizing the downside risk, whenever possible. All statements and expressions are the sole opinions of the editors and are subject to change without notice. This profile is neither an offer nor solicitation to buy or sell any securities mentioned. This newsletter is owned by SSP Management, Inc, a wholly owned subsidiary of 1st Net Technologies, Inc ("1st Net"). While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein. The editor, members of the editor's family, and/or entities with which they are affiliated, may own stock in and have other financial dealings with the companies who appear in the publication. To that degree, this newsletter should not be regarded to be an independent publication. SSP Management has received the following compensation for representing US Microbics for a period of one year: $50,000 in cash, and 50,000 options convertible into restricted stock, exercisable at $1 per share. In a related transaction, SSP Management intends to exercise its option by signing a promissory note to US Microbics for $50,000. The Stellarstocks.com critiques may contain forward looking statements relating to the expected capabilities of the companies mentioned herein.

THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED, WRITTEN CONSENT OF THE EDITORS OF STELLARSTOCKS.com.

We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission ("SEC") at http://www.sec.gov and/or the National Association of Securities Dealers ("NASD") at http://www.nasd.com. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at http://www.sec.gov/consumer/cyberfr.htm. Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site.